SYNLOGIC, INC. Increase (Decrease) in Accrued Liabilities
SYNLOGIC, INC. (SYBX) reported Increase (Decrease) in Accrued Liabilities of -$4.80 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-04.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2017-08-04
- SYNLOGIC, INC. increase (decrease) in accrued liabilities for the quarter ending 2017-06-30 was -$3.28M, a 1550.00% decline year-over-year.
- SYNLOGIC, INC. increase (decrease) in accrued liabilities for the quarter ending 2017-03-31 was -$1.52M.
- SYNLOGIC, INC. increase (decrease) in accrued liabilities for the quarter ending 2016-12-31 was -$1.53M, a 363.34% decline year-over-year.
- SYNLOGIC, INC. increase (decrease) in accrued liabilities for the quarter ending 2016-09-30 was -$250.00K.
- SYNLOGIC, INC. increase (decrease) in accrued liabilities for fiscal 2016 was -$1.80M, a 443.70% decline from fiscal 2015.
- SYNLOGIC, INC. increase (decrease) in accrued liabilities for fiscal 2015 was $524.00K, a 55.02% decline from fiscal 2014.
- SYNLOGIC, INC. increase (decrease) in accrued liabilities for fiscal 2014 was $1.17M, a 284.49% increase from fiscal 2013.
- SYNLOGIC, INC. increase (decrease) in accrued liabilities for fiscal 2013 was $303.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2017-06-30 | -$3.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | -$4.80M 10-Q · filed 2017-08-04 | -$6.33M derived: sum of 3 quarters · filed 2017-08-04 | -$6.58M derived: sum of 4 quarters · filed 2017-08-04 |
| 2017-03-31 | -$1.52M 10-Q · filed 2017-05-09 | -$3.05M derived: sum of 2 quarters · filed 2017-05-09 | -$3.30M derived: sum of 3 quarters · filed 2017-05-09 | -$3.08M derived: sum of 4 quarters · filed 2017-08-04 |
| 2016-12-31 | -$1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$1.78M derived: sum of 2 quarters · filed 2017-03-15 | -$1.55M derived: sum of 3 quarters · filed 2017-08-04 | -$1.80M 10-K · filed 2017-03-15 |
| 2016-09-30 | -$250.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$24.00K derived: sum of 2 quarters · filed 2017-08-04 | -$271.00K 10-Q · filed 2016-11-10 | $310.00K derived: sum of 4 quarters · filed 2017-08-04 |
| 2016-06-30 | $226.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | -$21.00K 10-Q · filed 2017-08-04 | $560.00K derived: sum of 3 quarters · filed 2017-08-04 | $501.00K derived: sum of 4 quarters · filed 2017-08-04 |
| 2016-03-31 | -$247.00K 10-Q · filed 2017-05-09 | $334.00K derived: sum of 2 quarters · filed 2017-05-09 | $275.00K derived: sum of 3 quarters · filed 2017-05-09 | $975.00K derived: sum of 4 quarters · filed 2017-05-09 |
| 2015-12-31 | $581.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $522.00K derived: sum of 2 quarters · filed 2017-03-15 | $1.22M derived: sum of 3 quarters · filed 2017-03-15 | $524.00K 10-K · filed 2017-03-15 |
| 2015-09-30 | -$59.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $641.00K derived: sum of 2 quarters · filed 2016-11-10 | -$57.00K 10-Q · filed 2016-11-10 | $745.00K derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $2.00K 10-Q · filed 2016-08-15 | $804.00K derived: sum of 3 quarters · filed 2017-03-15 | |
| 2015-03-31 | -$698.00K 10-Q · filed 2016-05-12 | $104.00K derived: sum of 2 quarters · filed 2017-03-15 | ||
| 2014-12-31 | $802.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $1.17M 10-K · filed 2017-03-15 | ||
| 2014-09-30 | $363.00K 10-Q · filed 2015-11-13 | |||
| 2013-12-31 | $303.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |